Previous 10 | Next 10 |
Gainers: TherapeuticsMD (TXMD) +361%. JanOne (JAN) +70%. Houston American Energy (HUSA) +57%. CatchMark Timber Trust (CTT) +44%. Mullen Automotive (MULN) +43%. Gogoro (GGR) +37%. BlackSky Technology (BKSY) +32%. Cassava Sciences (SAVA) +25%. MicroStrategy (MSTR) +24%. NexImmune (NEXI) +23%. L...
Gainers: TherapeuticsMD (TXMD) +355%. MoonLake Immunotherapeutics (MLTX) +24%. Gritstone bio (GRTS) +18%. Nurix Therapeutics (NRIX) +10%. DexCom (DXCM) +9%. Losers: Outlook Therapeutics (OTLK) -54%. Elevation Oncology (ELEV) -18%. SIGA Technologies (SIGA) -1...
Gainers: Elevation Oncology (ELEV) +20%. Cue Biopharma (CUE) +14%. Evelo Biosciences (EVLO) +13%. GeoVax Labs (GOVX) +13%. Immix Biopharma (IMMX) +9%. Losers: Verrica Pharmaceuticals (VRCA) -58%. PMV Pharmaceuticals (PMVP) -10%. TransMedics (TMDX) ...
3 Hot Biotech Penny Stocks to Add to Your Watchlist With the Market Down Recently, biotech penny stocks have seen heightened bullish sentiment. Today, the emphasis on biotech stocks comes as the Monkeypox virus is seeing a resurgence in certain areas around the world. Today, the WHO con...
Gainers: Immix Biopharma (IMMX) +48%. MDxHealth (MDXH) +31%. ClearPoint Neuro (CLPT) +16%. Covetrus (CVET) +14%. Kronos Bio (KRON) +13%. Losers: Evofem Biosciences (EVFM) -58%. Bright Green (BGXX) -26%. Foghorn Therapeutics (FHTX) -19%. N...
Nano-cap biotech Immix Biopharma (NASDAQ:IMMX) climbed in the morning hours Friday on above average volume after announcing that its lead asset IMX-110 outperformed an FDA-approved cancer drug marketed by Johnson & Johnson (JNJ) in a mice study. The connective tissue cancer soft tissue sa...
Immix Biopharma (NASDAQ:IMMX) on Friday announced positive data from animal study trial to test its lead candidate, IMX-110, ti treat Soft Tissue Sarcoma (STS). (IMMX) surged 60% before the bell. The study showed that after one cycle of treatment the drug produced 75% surv...
One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug) In a connective tissue cancer Soft Tissue Sarcoma (STS) mice study, IMX-110 was compared against approved drugs ...
Gainers: NeuroMetrix (NURO) +45%. Zealand Pharma (ZEAL) +18%. SIGA Technologies (SIGA) +16%. Indaptus Therapeutics (INDP) +15%. Immix Biopharma (IMMX) +13%. Losers: China SXT Pharmaceuticals (SXTC) -20%. Ocuphire Pharma (OCUP) -9%. Enanta Pharmaceu...
Immix Biopharma (NASDAQ:IMMX) said it has received Board's approval on Monday to repurchase up to $1M of its common shares. As of Apr. 15, 2022, the company had about 13.9M shares outstanding. "We are confident that with the $24.2 million gross proceeds raised in our recent IPO, ImmixBio is s...
News, Short Squeeze, Breakout and More Instantly...
LOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and...
Lead site Memorial Sloan Kettering Cancer Center (MSKCC) Timing of milestone in-line with mid-2024 guidance Data from ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate LOS ANGELES, July 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 4.6% to $128.28 on volume of 215,349,874 shares Zoomcar Holdings Inc. (ZCAR) rose 34.0% to $0.183 on volume of 204,010,215 shares Maxeon Solar Technologies Ltd. (MAXN) fell 3.5% to $0.1736 on volume of 2...